Meeting
2018 Gastrointestinal Cancers Symposium
A phase I study of veliparib (Vel) in combination with oxaliplatin (Ox) and capecitabine (Cap) in advanced solid tumors.
Authors
Anita Ahmed Turk
University of Wisconsin Carbone Cancer Center, Madison, WI
Anita Ahmed Turk , Dustin A. Deming , Sam Joseph Lubner , Daniel Mulkerin , Noelle K. LoConte , Amye Tevaarwerk , Kari Braun Wisinski , Jens C. Eickhoff , Glenn Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01233505
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 314)
DOI
10.1200/JCO.2018.36.4_suppl.314
Abstract #
314
Poster Bd #
E23
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors.
First Author: Jin Li
Poster
2019 ASCO Annual Meeting
Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.
First Author: Junning Cao
Poster
2018 ASCO Annual Meeting
Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors.
First Author: Geraldine Helen O'Sullivan Coyne
Poster
2013 ASCO Annual Meeting
Phase I study of ABT-888 in combination with carboplatin and gemcitabine in subjects with advanced solid tumors.
First Author: Katherine M. Bell-McGuinn